Vascular Biogenics (NASDAQ:VBLT) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.03), Fidelity Earnings reports. The company had revenue of $0.16 million during the quarter.
Shares of NASDAQ:VBLT traded down $0.05 during trading on Friday, hitting $2.15. 15,184 shares of the stock were exchanged, compared to its average volume of 310,601. Vascular Biogenics has a 1-year low of $2.22 and a 1-year high of $2.22. The firm has a market capitalization of $66.52 million, a PE ratio of -5.81 and a beta of -1.69.
A number of analysts have issued reports on VBLT shares. Zacks Investment Research lowered Vascular Biogenics from a “hold” rating to a “sell” rating in a report on Thursday, January 25th. ValuEngine raised Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. HC Wainwright lowered Vascular Biogenics from a “buy” rating to a “neutral” rating and set a $3.00 target price on the stock. in a report on Thursday, March 8th. Piper Jaffray lowered Vascular Biogenics from an “overweight” rating to a “neutral” rating and set a $4.00 target price on the stock. in a report on Thursday, March 8th. Finally, JMP Securities lowered Vascular Biogenics from an “outperform” rating to a “market perform” rating in a report on Thursday, March 8th. One research analyst has rated the stock with a sell rating and five have issued a hold rating to the company’s stock. Vascular Biogenics currently has an average rating of “Hold” and an average target price of $3.19.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.